Labcorp Finalizes Acquisition of Select Assets of Invitae
Labcorp (NYSE: LH) has completed its acquisition of select assets from Invitae (OTC:NVTAQ), a leading medical genetics company. This strategic move extends Labcorp's leadership in genetic testing solutions, particularly in oncology and select rare diseases. The acquisition aims to enhance Labcorp's specialty testing capabilities and improve its ability to utilize genetic data in clinical trials and treatment regimens.
By integrating Invitae's genetic testing technology with Labcorp's existing capabilities, the company will offer more comprehensive insights for patients, from testing to diagnosis and treatment. This collaboration is expected to support patients, clinicians, and pharmaceutical partners across the continuum of care, including therapy development, patient diagnosis, and personalized care.
Labcorp (NYSE: LH) ha completato l'acquisizione di seleziona beni da Invitae (OTC:NVTAQ), una delle principali aziende nel campo della genetica medica. Questa mossa strategica estende la leadership di Labcorp nelle soluzioni di test genetici, in particolare in oncologia e in alcune malattie rare. L'acquisizione mira a potenziare le capacità di testing specialistiche di Labcorp e a migliorare la sua capacità di utilizzare i dati genetici nelle sperimentazioni cliniche e nei regimi di trattamento.
Integrando la tecnologia di test genetici di Invitae con le capacità esistenti di Labcorp, l'azienda potrà offrire informazioni più complete per i pazienti, dal test alla diagnosi e al trattamento. Questa collaborazione dovrebbe supportare pazienti, clinici e partner farmaceutici lungo l'intero percorso di cura, inclusi lo sviluppo della terapia, la diagnosi del paziente e le cure personalizzate.
Labcorp (NYSE: LH) ha completado la adquisición de activos selectos de Invitae (OTC:NVTAQ), una empresa líder en genética médica. Este movimiento estratégico extiende el liderazgo de Labcorp en soluciones de pruebas genéticas, particularmente en oncología y en ciertas enfermedades raras. La adquisición tiene como objetivo mejorar las capacidades de pruebas especializadas de Labcorp y aumentar su capacidad para utilizar datos genéticos en ensayos clínicos y esquemas de tratamiento.
Al integrar la tecnología de pruebas genéticas de Invitae con las capacidades existentes de Labcorp, la empresa ofrecerá información más completa para los pacientes, desde la prueba hasta el diagnóstico y tratamiento. Se espera que esta colaboración apoye a pacientes, clínicos y socios farmacéuticos a lo largo del continuum de atención, incluyendo el desarrollo de terapias, el diagnóstico del paciente y la atención personalizada.
랩코프(Labcorp, NYSE: LH)가 인비테(Invitae, OTC:NVTAQ)로부터 선택된 자산의 인수를 완료했습니다. 인비테는 선도적인 의료 유전학 회사입니다. 이 전략적 결정은 랩코프의 유전자 검사 솔루션의 리더십을 확장합니다, 특히 종양학 및 일부 희귀 질병 분야에서. 인수의 목적은 랩코프의 특수 검사 능력을 향상시키고 임상 시험 및 치료 계획에서 유전 데이터를 활용하는 능력을 개선하는 것입니다.
인비테의 유전자 검사 기술을 랩코프의 기존 능력과 통합함으로써, 회사는 환자를 위한 보다 포괄적인 통찰력을 제공할 것입니다, 검사부터 진단 및 치료까지. 이 협력은 환자, 임상의, 제약 파트너들이 치료 개발, 환자 진단 및 맞춤형 치료를 포함한 전반적인 치료 과정에서 지원할 것으로 기대됩니다.
Labcorp (NYSE: LH) a achevé l'acquisition de certains actifs d'Invitae (OTC:NVTAQ), une entreprise leader dans le domaine de la génétique médicale. Ce mouvement stratégique étend le leadership de Labcorp dans les solutions de tests génétiques, particulièrement en oncologie et dans certaines maladies rares. L'acquisition vise à améliorer les capacités de tests spécialisés de Labcorp et à renforcer sa capacité à utiliser des données génétiques dans les essais cliniques et les régimes de traitement.
En intégrant la technologie de test génétique d'Invitae avec les capacités existantes de Labcorp, l'entreprise proposera des informations plus complètes pour les patients, depuis le test jusqu'au diagnostic et au traitement. Cette collaboration devrait soutenir les patients, les cliniciens et les partenaires pharmaceutiques tout au long du continuum de soins, y compris le développement de thérapies, le diagnostic des patients et les soins personnalisés.
Labcorp (NYSE: LH) hat die Übernahme ausgewählter Vermögenswerte von Invitae (OTC:NVTAQ), einem führenden Unternehmen der medizinischen Genetik, abgeschlossen. Dieser strategische Schritt erweitert Labcorps Führungsrolle im Bereich genetischer Testlösungen, insbesondere in der Onkologie und bei bestimmten seltenen Krankheiten. Das Ziel der Übernahme ist es, Labcorps Spezialtestfähigkeiten zu verbessern und die Fähigkeit zu optimieren, genetische Daten in klinischen Studien und Behandlungsregimen zu nutzen.
Durch die Integration der genetischen Testtechnologie von Invitae mit den bestehenden Fähigkeiten von Labcorp wird das Unternehmen umfassendere Einblicke für Patienten anbieten, von Tests über Diagnosen bis hin zu Behandlungen. Diese Zusammenarbeit soll Patienten, Kliniker und pharmazeutische Partner entlang des gesamten Versorgungskontinuums unterstützen, einschließlich der Therapieentwicklung, der Patienten Diagnostik und der personalisierten Versorgung.
- Expansion of Labcorp's specialty testing capabilities in genetic testing
- Enhanced ability to utilize genetic data in clinical trials and treatment regimens
- More comprehensive patient insights from testing to diagnosis and treatment
- Strengthened position in oncology and rare disease genetic testing markets
- None.
The acquisition of select Invitae assets by Labcorp is a strategic move that could significantly enhance Labcorp's position in the genetic testing market. This deal likely strengthens Labcorp's competitive edge, particularly in oncology and rare disease diagnostics.
While specific financial details are not disclosed, the acquisition's impact on Labcorp's future revenue and market share could be substantial. Investors should watch for potential synergies and cost efficiencies resulting from the integration of Invitae's technology and talent. The expanded capabilities in genetic testing may also open new revenue streams, especially in personalized medicine and clinical trials support.
However, the success of this acquisition will depend on Labcorp's ability to effectively integrate Invitae's assets and capitalize on the combined expertise. Investors should monitor upcoming quarterly reports for signs of successful integration and its impact on Labcorp's financial performance.
Labcorp's acquisition of Invitae's assets marks a significant advancement in the field of genetic testing and personalized medicine. This merger combines Labcorp's extensive laboratory services with Invitae's cutting-edge genetic technology, potentially accelerating breakthroughs in oncology and rare disease research.
The integration of these assets could lead to more comprehensive genetic testing panels, improving diagnostic accuracy and treatment selection. This is particularly important in oncology, where genetic insights increasingly drive targeted therapies. For rare diseases, expanded testing capabilities may lead to earlier diagnoses and better patient outcomes.
Moreover, the combined entity's ability to leverage genetic data in clinical trials could expedite drug development processes, potentially bringing new treatments to market faster. Investors should watch for announcements of new research collaborations or expanded clinical trial services as indicators of the acquisition's success in advancing medical research.
This acquisition positions Labcorp to capitalize on the rapidly growing genetic testing market, which is projected to reach
The deal aligns with the industry trend towards consolidation and vertical integration in the diagnostics sector. It allows Labcorp to offer a more comprehensive suite of services, potentially attracting more pharmaceutical partners for clinical trials and research collaborations.
However, the genetic testing market is highly competitive, with players like Illumina and Exact Sciences also expanding their offerings. Labcorp will need to leverage this acquisition effectively to maintain its competitive edge. Investors should monitor how this acquisition impacts Labcorp's market position and whether it leads to increased partnerships with pharmaceutical companies or healthcare providers.
Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases
"Labcorp and Invitae are on a shared mission to harness the power of genetic insights to transform medicine, deliver personalized care and improve health outcomes," said Mark Schroeder, Executive Vice President and President of Diagnostics Laboratories and Chief Operations Officer of Labcorp. "By adding Invitae's cutting edge science and industry-leading experience, we will extend our leadership in genetic testing solutions with the most comprehensive offerings in areas such as oncology and select rare diseases. We are excited to welcome Invitae's talented team to Labcorp and look forward to bringing genetic testing solutions to patients and physicians to improve health and improve lives."
The acquisition expands Labcorp's specialty testing capabilities and the company's ability to utilize genetic data to improve clinical trials and treatment regimens in oncology and select rare diseases. By integrating Invitae's genetic testing technology with Labcorp's specialty testing capabilities, the company will offer a more complete set of insights for each patient – from testing to diagnosis to treatment.
For more information visit Labcorp.com/invitae.
Invitae is advised by Kirkland & Ellis LLP as legal counsel, Moelis & Company LLC as investment banker and FTI Consulting, Inc. as financial and communications advisor. Citi is serving as Labcorp's financial advisor and Hogan Lovells and Kilpatrick Townsend are serving as Labcorp's legal counsel.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to the company's acquisition of select assets of Invitae and the anticipated benefits of the transaction for the company, providers and patients.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC, including the information in the company's most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-finalizes-acquisition-of-select-assets-of-invitae-302214260.html
SOURCE Labcorp
FAQ
What assets did Labcorp acquire from Invitae?
How will the Invitae acquisition impact Labcorp's (LH) genetic testing capabilities?
What are the expected benefits of Labcorp's acquisition of Invitae assets?
How does the Invitae asset acquisition align with Labcorp's (LH) business strategy?
